Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1

Interventions

fludarabine phosphate 4Cyclosporine 3Cyclophosphamide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3ruxolitinib 2fludarabine 2Whole-Body Irradiation 2Stem Cell Transplantation 2Radiotherapy 2Methylprednisolone 2Busulfan 2Antilymphocyte Serum 2nelarabine 1arsenous acid 1anagrelide 1Watchful Waiting 1Thiotepa 1Tetradecanoylphorbol Acetate 1Surveys and Questionnaires 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Observation 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Moxifloxacin 1Morphine 1Methotrexate 1Methadone 1Liposomes 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thrombocythemia, Essential × arsenous acid × Clear all
NCT01014546 2022-07-22

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Roswell Park Cancer Institute

Phase 1 Terminated
5 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡